Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2013145.pdf
Reference35 articles.
1. Amir E, Seruga B, Kwong R, Tannock IF, Ocana A (2012) Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer 48: 385–388.
2. Beaumont JL, Butt Z, Baladi J, Motzer RJ, Haas T, Hollaender N, Kay A, Cella D (2011) Patient-reported outcomes in a phase III Study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. Oncologist 16: 632–640.
3. Bukowski R, Cella D, Gondek K, Escudier B (2007) Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30: 220–227.
4. Butt Z, Peipert J, Webster K, Chen C, Cella D (2012) General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). Cancer 119: 429–437.
5. Cella D (2009) Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev 35: 733–737.
Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma—Systematic Literature Review of Clinical and Real-World Evidence;Cancers;2024-07-30
2. Exploring the multifaceted antitumor activity of axitinib in lung carcinoids;Frontiers in Endocrinology;2024-07-10
3. Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma;Journal of Kidney Cancer and VHL;2022-09-29
4. Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing;Genome Biology;2022-03-31
5. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial;The Lancet Oncology;2022-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3